A roundup of the latest news and updates for patients with myeloma from CURE®.
There have been several updates in the field of myeloma over the last several weeks. Here, CURE® looks back at some of the latest news and updates affecting patients with the disease.
In addition to improving progression-free survival (PFS) in patients with multiple myeloma who have undergone an autologous stem cell transplant, Ninlaro (ixazomib) is also well-tolerated, with low-grade, manageable side effects, according to results of the TOURMALINE-MM3 study.
A triplet regimen of Kyprolis (carfilzomib), Revlimid and dexamethasone (KRd) was not superior to the standard of care Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone (VRd) in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, according to data published in Lancet Oncology.
Updated results from a phase 2 trial show that treatment with CLR 131 appears effective in inducing an overall response in patients with multiple myeloma whose disease is deemed triple-class refractory, according to a press release from Cellectar Biosciences.
Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology.
CURE® recently spoke with Mary DeRome, director of medical communications and education at the Multiple Myeloma Research Foundation (MMRF) in Norwalk, Connecticut, about her organization’s collaboration with other cancer groups to ensure patients get the best possible treatment.
